ATE474838T1 - Benzimidazolderivate als faktor xa-inhibitoren - Google Patents

Benzimidazolderivate als faktor xa-inhibitoren

Info

Publication number
ATE474838T1
ATE474838T1 AT04731162T AT04731162T ATE474838T1 AT E474838 T1 ATE474838 T1 AT E474838T1 AT 04731162 T AT04731162 T AT 04731162T AT 04731162 T AT04731162 T AT 04731162T AT E474838 T1 ATE474838 T1 AT E474838T1
Authority
AT
Austria
Prior art keywords
inhibitors
factor
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Application number
AT04731162T
Other languages
English (en)
Inventor
Marc Nazare
Michael Wagner
Volkmar Wehner
Hans Matter
Matthias Urmann
Kurt Ritter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33040952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE474838(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE474838T1 publication Critical patent/ATE474838T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT04731162T 2003-05-19 2004-05-05 Benzimidazolderivate als faktor xa-inhibitoren ATE474838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011305A EP1479676A1 (de) 2003-05-19 2003-05-19 Benzimidazolderivate als Faktor Xa-Inhibitoren
PCT/EP2004/004750 WO2004101553A1 (en) 2003-05-19 2004-05-05 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
ATE474838T1 true ATE474838T1 (de) 2010-08-15

Family

ID=33040952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731162T ATE474838T1 (de) 2003-05-19 2004-05-05 Benzimidazolderivate als faktor xa-inhibitoren

Country Status (30)

Country Link
EP (2) EP1479676A1 (de)
JP (1) JP4658940B2 (de)
KR (1) KR20060014056A (de)
CN (2) CN101139346A (de)
AR (1) AR045683A1 (de)
AT (1) ATE474838T1 (de)
AU (1) AU2004238497B2 (de)
BR (1) BRPI0410446A (de)
CA (1) CA2526065A1 (de)
CL (1) CL2004001078A1 (de)
CR (1) CR8087A (de)
DE (1) DE602004028240D1 (de)
EC (1) ECSP056178A (de)
HK (1) HK1089174A1 (de)
MA (1) MA27798A1 (de)
MX (1) MXPA05012231A (de)
NO (1) NO20055910L (de)
NZ (1) NZ543670A (de)
OA (1) OA13168A (de)
PA (1) PA8603501A1 (de)
PE (1) PE20050198A1 (de)
RS (1) RS20050856A (de)
RU (1) RU2346944C2 (de)
SA (1) SA04250196B1 (de)
TN (1) TNSN05297A1 (de)
TW (1) TW200503696A (de)
UA (1) UA82100C2 (de)
UY (1) UY28324A1 (de)
WO (1) WO2004101553A1 (de)
ZA (1) ZA200508151B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
EP3085700B1 (de) * 2013-12-20 2018-10-31 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Neuartige piperidincarboxamidverbindung, herstellungsverfahren und verwendung davon
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1377642A (en) * 1971-01-14 1974-12-18 Koninklijke Gist Spiritus Penicillanic and cephalosporanic acid derivatives
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
DE3828537A1 (de) * 1988-08-23 1990-03-01 Basf Ag Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material
JPH0324609A (ja) * 1989-06-21 1991-02-01 Mitsuba Electric Mfg Co Ltd I/o用バッファic
JPH03184043A (ja) * 1989-12-14 1991-08-12 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH08208640A (ja) * 1995-02-06 1996-08-13 Nisshin Flour Milling Co Ltd ベンズイミダゾール誘導体およびそれを含有する心不全治療薬
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JPH09124609A (ja) * 1995-11-07 1997-05-13 Nissan Chem Ind Ltd ベンズイミダゾール誘導体
JPH10182459A (ja) * 1996-12-26 1998-07-07 Otsuka Pharmaceut Co Ltd cGMP分解酵素阻害剤
US6562828B1 (en) * 1998-04-10 2003-05-13 Japan Tobacco Inc. Amidine compounds
AU2003265886A1 (en) * 2002-09-06 2004-03-29 Janssen Pharmaceutica N.V. (1H-Benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders

Also Published As

Publication number Publication date
PA8603501A1 (es) 2004-11-26
ZA200508151B (en) 2007-02-28
NO20055910L (no) 2006-02-10
RU2005139555A (ru) 2006-06-10
WO2004101553A1 (en) 2004-11-25
EP1636216B1 (de) 2010-07-21
WO2004101553B1 (en) 2005-03-03
EP1479676A1 (de) 2004-11-24
AU2004238497B2 (en) 2010-07-22
AU2004238497A1 (en) 2004-11-25
CN1791598A (zh) 2006-06-21
ECSP056178A (es) 2006-08-30
MA27798A1 (fr) 2006-03-01
NZ543670A (en) 2008-09-26
CA2526065A1 (en) 2004-11-25
CN100484935C (zh) 2009-05-06
UA82100C2 (uk) 2008-03-11
EP1636216A1 (de) 2006-03-22
KR20060014056A (ko) 2006-02-14
BRPI0410446A (pt) 2006-06-06
CL2004001078A1 (es) 2005-04-08
UY28324A1 (es) 2004-12-31
DE602004028240D1 (de) 2010-09-02
OA13168A (en) 2006-12-13
JP2006528213A (ja) 2006-12-14
JP4658940B2 (ja) 2011-03-23
PE20050198A1 (es) 2005-04-25
CR8087A (es) 2006-09-22
RU2346944C2 (ru) 2009-02-20
TNSN05297A1 (en) 2007-07-10
CN101139346A (zh) 2008-03-12
RS20050856A (en) 2007-11-15
MXPA05012231A (es) 2006-08-18
TW200503696A (en) 2005-02-01
SA04250196B1 (ar) 2008-11-18
HK1089174A1 (en) 2006-11-24
AR045683A1 (es) 2005-11-09

Similar Documents

Publication Publication Date Title
ATE444292T1 (de) Pyrazolderivate als faktor-xa-inhibitoren
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
IS7667A (is) Nýjar bensimídazólafleiður
ATE520684T1 (de) Neue carbonsäureamide als faktor xa-inhibitoren
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE521607T1 (de) Piperidinderivate als renin-inhibitoren
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
DK1663232T3 (da) Benzimidazolderivater som human chymase-inhibitorer
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
NO20042592L (no) Indol-2-karboksamider som faktor XA inhibitorer
ATE449605T1 (de) N3-alkylierte benzimidazol-derivate als mek- hemmer
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DK1626964T3 (da) Nye benzimidazolderivater
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
ATE401328T1 (de) Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren
ATE386518T1 (de) Benzimidazolderivate
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
DE60203006D1 (de) Pyrrolidin-derivate als faktor xa inhibitoren
NO20042990L (no) Pyrrolidin-2-oner som faktor XA inhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties